311 related articles for article (PubMed ID: 29496411)
41. Discovery of novel 2-substituted-4-phenoxypyridine derivatives as potential antitumor agents.
Duan Y; Xu S; Xiong H; Wang L; Zhao B; Wang P; Wang C; Peng Y; Cai S; Luo R; Zheng P; Tang Q
Bioorg Med Chem Lett; 2018 Feb; 28(3):254-259. PubMed ID: 29317165
[TBL] [Abstract][Full Text] [Related]
42. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds.
Abdellatif KRA; Bakr RB
Bioorg Chem; 2018 Aug; 78():341-357. PubMed ID: 29627655
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
44. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Zhang Y; Chen L; Xu H; Li X; Zhao L; Wang W; Li B; Zhang X
Eur J Med Chem; 2018 Mar; 147():77-89. PubMed ID: 29421573
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis and anti-fibrosis evaluation of imidazo[1,2-a]pyridine derivatives as potent ATX inhibitors.
Chen Y; Lei H; Li T; Cui Y; Wang X; Cao Z; Wu H; Zhai X
Bioorg Med Chem; 2021 Sep; 46():116362. PubMed ID: 34428714
[TBL] [Abstract][Full Text] [Related]
46. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
47. EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor.
Elkamhawy A; Hassan AHE; Paik S; Sup Lee Y; Lee HH; Shin JS; Lee KT; Roh EJ
Bioorg Chem; 2019 May; 86():112-118. PubMed ID: 30685642
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and anticancer activity of some pyrido[2,3-
Abbas SE; George RF; Samir EM; Aref MM; Abdel-Aziz HA
Future Med Chem; 2019 Sep; 11(18):2395-2414. PubMed ID: 31544523
[No Abstract] [Full Text] [Related]
50. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
52. Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
Farag AK; Elkamhawy A; Londhe AM; Lee KT; Pae AN; Roh EJ
Eur J Med Chem; 2017 Dec; 141():657-675. PubMed ID: 29107425
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, toxicities and bio-activities of manganese complexes with CO and H
Bai Z; Zhang J; Zhang Q; Zhang T; Li J; Zhao Q; Wang Z; He D; Cheng J; Zhang J; Liu B
Eur J Med Chem; 2018 Nov; 159():339-356. PubMed ID: 30308409
[TBL] [Abstract][Full Text] [Related]
54. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
55. Synthesis, cytotoxicity, antimicrobial and anti-biofilm activities of novel pyrazolo[3,4-b]pyridine and pyrimidine functionalized 1,2,3-triazole derivatives.
Nagender P; Malla Reddy G; Naresh Kumar R; Poornachandra Y; Ganesh Kumar C; Narsaiah B
Bioorg Med Chem Lett; 2014 Jul; 24(13):2905-8. PubMed ID: 24835633
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Chang S; Zhang L; Xu S; Luo J; Lu X; Zhang Z; Xu T; Liu Y; Tu Z; Xu Y; Ren X; Geng M; Ding J; Pei D; Ding K
J Med Chem; 2012 Mar; 55(6):2711-23. PubMed ID: 22339342
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors.
Saurat T; Buron F; Rodrigues N; de Tauzia ML; Colliandre L; Bourg S; Bonnet P; Guillaumet G; Akssira M; Corlu A; Guillouzo C; Berthier P; Rio P; Jourdan ML; Bénédetti H; Routier S
J Med Chem; 2014 Feb; 57(3):613-31. PubMed ID: 24345273
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
[TBL] [Abstract][Full Text] [Related]
60. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
